CTRI/2022/02/040350尚未招募未知
Open Labeled, Non-randomized study, to investigate the effect of Free Online Yoga Classes for Subjects on Self Home Isolation in COVID-19
Kamlesh Kumar Mishra0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients who are ready to give Consent.
- •Patients who tested positive for COVID-19.
- •Clinically mild Patients in home isolation.
排除标准
- •Patients whose SpO2 is less than 95
- •Patient having high grade fever ( > 99 F)
- •Patient having any other co-morbidity.
研究者
相似试验
尚未招募
Unknown
A Study Investigating the Coolio System for Pain Management in Patients with Osteoarthritis of the KneeOsteoarthritis of the kneePain managementMusculoskeletal - OsteoarthritisAnaesthesiology - Pain managementACTRN12624000250538Brixton Biosciences6
已完成
不适用
OPEN-LABEL, NON-RANDOMIZED STUDY INVESTIGATING THE EXCRETION BALANCE, PHARMACOKINETICS, AND METABOLISM OF A SINGLE INTRAVENOUS DOSE OF [14C]-LABELED RO7223280 IN HEALTHY MALE PARTICIPANTSNL-OMON51844F. Hoffmann-La Roche Ltd.6
进行中（未招募）
1 期
An open-label, non-randomized trial to investigate the efficacy and safety of early versus delayed start of arimoclomol in patients with sporadic inclusion body myositis who have completed the IBM4809 trialSporadic Inclusion Body Myositis (sIBM)MedDRA version: 21.1Level: LLTClassification code 10075052Term: Sporadic inclusion body myositisSystem Organ Class: 100000004859EUCTR2019-000749-11-GBOrphazyme A/S130
已完成
不适用
A non-interventional study looking at safety and efficacy of medicinal cannabis prescribed to patients with symptoms of Irritable Bowel Syndrome (IBS).Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonIrritable Bowel SyndromeACTRN12621000102875Emyria Limited50
已完成
不适用
Open-label, non-randomized study investigating the excretion balance, Pharmacokinetics, and metabolism of a single oral dose of [14c]-labeled ro6868847 in healthy male participantsDiabetic retinopathy10012653DiabetesNL-OMON51247F. Hoffmann-La Roche Ltd10